Aura Biosciences Q3 net loss widens as R&D costs rise

Reuters11-13

<a href="https://laohu8.com/S/AURA">Aura Biosciences</a> Q3 net loss widens as R&D costs rise

Overview

Aura Biosciences reports Q3 net loss of $26.1 mln, up from $21.0 mln last year
R&D expenses rise to $22.2 mln due to ongoing clinical trials

Outlook

Aura expects Phase 3 CoMpass trial enrollment completion in 2026
Topline data for CoMpass trial expected in Q4 2027
Phase 1b/2 trial data for NMIBC expected mid-2026

Result Drivers

ENROLLMENT CHALLENGES - CoMpass trial enrollment faced delays due to requirement for active tumor growth and operational challenges, now improved
R&D EXPENSES - Increased due to ongoing clinical trials and personnel growth

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Net Income		-$26.13 mln
Q3 Operating Expenses		$27.91 mln
Q3 Operating Income		-$27.91 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Aura Biosciences Inc is $21.00, about 73.5% above its November 12 closing price of $5.57

Press Release: ID:nGNX2Ws1Nw

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583256215?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 20:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583256215","market":"us","top_or_hot":-1,"title":"Aura Biosciences Q3 net loss widens as R&D costs rise","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/AURA\">Aura Biosciences</a> Q3 net loss widens as R&amp;D costs rise</title></head><body><p><span>Overview</span></p><ul><li><p>Aura Biosciences reports Q3 net loss of $26.1 mln, up from $21.0 mln last year</p></li><li><p>R&amp;D expenses rise to $22.2 mln due to ongoing clinical trials</p></li></ul><p><span>Outlook</span></p><ul><li><p>Aura expects Phase 3 CoMpass trial enrollment completion in 2026</p></li><li><p>Topline data for CoMpass trial expected in Q4 2027</p></li><li><p>Phase 1b/2 trial data for NMIBC expected mid-2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>ENROLLMENT CHALLENGES - CoMpass trial enrollment faced delays due to requirement for active tumor growth and operational challenges, now improved</p></li><li><p>R&amp;D EXPENSES - Increased due to ongoing clinical trials and personnel growth</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$26.13 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$27.91 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$27.91 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Aura Biosciences Inc is $21.00, about 73.5% above its November 12 closing price of $5.57</p></li></ul><p>Press Release: <span>ID:nGNX2Ws1Nw</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aura Biosciences Q3 net loss widens as R&D costs rise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAura Biosciences Q3 net loss widens as R&D costs rise\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-13 20:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/AURA\">Aura Biosciences</a> Q3 net loss widens as R&amp;D costs rise</title></head><body><p><span>Overview</span></p><ul><li><p>Aura Biosciences reports Q3 net loss of $26.1 mln, up from $21.0 mln last year</p></li><li><p>R&amp;D expenses rise to $22.2 mln due to ongoing clinical trials</p></li></ul><p><span>Outlook</span></p><ul><li><p>Aura expects Phase 3 CoMpass trial enrollment completion in 2026</p></li><li><p>Topline data for CoMpass trial expected in Q4 2027</p></li><li><p>Phase 1b/2 trial data for NMIBC expected mid-2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>ENROLLMENT CHALLENGES - CoMpass trial enrollment faced delays due to requirement for active tumor growth and operational challenges, now improved</p></li><li><p>R&amp;D EXPENSES - Increased due to ongoing clinical trials and personnel growth</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$26.13 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$27.91 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$27.91 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Aura Biosciences Inc is $21.00, about 73.5% above its November 12 closing price of $5.57</p></li></ul><p>Press Release: <span>ID:nGNX2Ws1Nw</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL1N3WP0GD:1","article_id":"2583256215","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583256215","pubTimestamp":1763035913,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aura Biosciences Q3 net loss widens as R&D costs riseOverviewAura Biosciences reports Q3 net loss of $26.1 mln, up from $21.0 mln last yearR&D expenses rise to $22.2 mln due to ongoing clinical trials","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","AURA":"Aura Biosciences, Inc."},"translate_title":"随着研发成本上升，Aura Biosciences第三季度净亏损扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AURA":0.9},"content_text":"Aura Biosciences Q3 net loss widens as R&D costs riseOverviewAura Biosciences reports Q3 net loss of $26.1 mln, up from $21.0 mln last yearR&D expenses rise to $22.2 mln due to ongoing clinical trialsOutlookAura expects Phase 3 CoMpass trial enrollment completion in 2026Topline data for CoMpass trial expected in Q4 2027Phase 1b/2 trial data for NMIBC expected mid-2026Result DriversENROLLMENT CHALLENGES - CoMpass trial enrollment faced delays due to requirement for active tumor growth and operational challenges, now improvedR&D EXPENSES - Increased due to ongoing clinical trials and personnel growthKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Net Income-$26.13 mlnQ3 Operating Expenses$27.91 mlnQ3 Operating Income-$27.91 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Aura Biosciences Inc is $21.00, about 73.5% above its November 12 closing price of $5.57Press Release: ID:nGNX2Ws1NwFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583256215","isCrawlerRequest":true}